Bicycle Therapeutics Plc (BCYC) - News Archive

Innovative Advances in Urothelial Cancer Treatment: Bicycle Therapeutics Updates on Zelenectide Pevedotin and Future DirectionsBicycle Therapeutics plc (NASDAQ: BCYC), a pioneer at the forefront of pharmaceutical innova...

Breakthrough Developments in NECTIN4-Targeted Therapy Amid Revenue Challenges for Bicycle Therapeutics Bicycle Therapeutics Reports Promising Zelenectide Pevedotin Data While Grappling with Market Competition In an era...

Bicycle Therapeutics plc is at the forefront of pioneering a new and highly differentiated class of therapeutics based on its proprietary bicyclic peptide technology. The company s recent announcements regarding present...

In a significant move for breast cancer therapeutics, Bicycle Therapeutics plc, a trailblazer in pioneering innovative treatment modalities, has announced an upcoming presentation at the esteemed 2024 San Antonio Breast...

CAMBRIDGE, England & BOSTON Bicycle Therapeutics plc (NASDAQ: BCYC), a company dedicated to advancing a new class of therapeutics through its proprietary bicyclic peptide technology, has reported significant business pr...

Bicycle Therapeutics (NASDAQ: BCYC) continues to drive innovation in the pharmaceutical industry with its unique bicyclic peptide (Bicycle) technology. This article provides an overview of the company s recent business...

Bicycle Therapeutics, a leading pharmaceutical company specializing in the development of innovative therapeutics, has recently shared exciting updates regarding their Phase 1/2 clinical trials. The company s proprietar...

: Bicycle Therapeutics plc, a pioneering biopharmaceutical company, has developed a novel class of therapeutics based on proprietary bicyclic peptide (Bicycle) technology. The company has recently disseminated promising...

Bicycle Therapeutics to Showcase Groundbreaking Therapies at 2024 AACR Annual MeetingCAMBRIDGE, England & BOSTON - Bicycle Therapeutics plc (NASDAQ: BCYC), a trailblazing biopharmaceutical company specializing in innova...